Last reviewed · How we verify

NCT04971564: RADICAL

Thrombo-inflammation Biomarkers Trial in Acute Cerebral Hypoxia

Recruiting now Last updated 22 January 2026
What this trial tests

trial testing Blood sampling in Cerebral Hypoxia in 200 participants. Currently enrolling.

Timeline
19 March 2024
Primary endpoint
22 June 2026
22 June 2026

Quick facts

Lead sponsorFondation Ophtalmologique Adolphe de Rothschild
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment200
Start date19 March 2024
Primary completion22 June 2026
Estimated completion22 June 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Cerebral Hypoxia or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood sampling

Trials testing the same drug.

Other recruiting trials for Cerebral Hypoxia

Currently open trials in the same condition.

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04971564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing